Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 542 of 5804
-
New drug cocktail aims to fight head and neck cancer
Disease control Recruiting nowThe purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metast…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy hope for SMA kids: early trial launches
Disease control OngoingThis study is a single-center, open-label, single-arm, non-randomized, single-dose, dose-escalation investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of NKG001 Injection administered via different dosing regimens (intraveno…
Phase: NA • Sponsor: Nikegen Pharmaceutical (Hangzhou) Company Limited • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo targets tough lung cancer with promising drug
Disease control OngoingThe purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New vaccine targets 24 pneumococcal strains in major trial
⭐️ VACCINE ⭐️ OngoingA phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older. The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is…
Phase: PHASE2 • Sponsor: Shanghai Reinovax Biologics Co.,LTD • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take on relapsed blood cancers
Disease control Recruiting now1. Study Title: A Study on the Efficacy and safety of Autocrine p40-Expressing CD19-Targeted Chimeric Antigen Receptor T Cells (CD19-CAR.p40-T) in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies 2. Study Objectives: 2.1.1 Primary Objective To eval…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a simple supplement shield bones and kidneys from common heartburn drugs?
Prevention TerminatedProton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragili…
Phase: PHASE3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Weekly insulin shot could replace daily pokes for diabetes
Disease control CompletedThis study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment pa…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo aims to tackle untreated lymphoma
Disease control Recruiting nowThe purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Simple blood test could spot cancer earlier in High-Risk individuals
Diagnosis Recruiting nowThe goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer det…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Magic mushroom therapy takes on tough depression
Symptom relief OngoingThe goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: * Does psilocybin with assisted therapy help improve symptoms for people with depression? * How long do the…
Phase: PHASE3 • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New blood filter could save lives in septic shock
Disease control OngoingThis study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and ol…
Phase: NA • Sponsor: ExThera Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take on childhood cancer in early trial
Disease control OngoingMAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating…
Phase: PHASE1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Magic mushroom compound tested as One-Time depression fix for cancer patients
Symptom relief Recruiting nowThe goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of…
Phase: PHASE2 • Sponsor: Section for Affective Disorders; Northern Stockholm Psychiatry • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
AI takes the guesswork out of insulin dosing for hospital patients
Disease control CompletedOur study was a single-blind, randomised, controlled, multicentre study. The study was planned to enrol 142 patients with T2DM admitted to general wards who required subcutaneous insulin therapy. Participants were randomly divided into two groups in the ratio of 1:1, one group wi…
Phase: NA • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail targets tough colorectal cancer
Disease control OngoingThe aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.
Phase: PHASE2 • Sponsor: Jing-yuan Fang, MD, Ph. D • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Gene therapy breakthrough? early trial for blood disorder shows promise
Disease control CompletedThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-thalassemia major anemia.
Phase: PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New targeted therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThe main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat lung cancer
Disease control Recruiting nowThe purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung cancer.
Phase: PHASE1, PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immune cells from your tumor could fight cancer again
Disease control Recruiting nowThis study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307 injection ) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determin…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New CAR t therapy aims to tackle tough leukemia
Disease control Recruiting nowThe purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC